Skip to main content
OpenTrials
Completed

NCT Number: NCT03637504

Feasibility of a Mobile Medication Plan Application in CF Patient Care

This is a pilot, multicenter, prospective, randomized controlled study to evaluate the feasibility of an innovative medication adherence intervention utilizing a web-based, mobile medication management application [MedActionPlan® (MAP)] to encourage self-management by reinforcing adherence and education about treatment regimens in Participants with cystic fibrosis (CF) (ages 12 years and older).

Outcomes of interest for this study are 1) feasibility of MAP in real-world setting which will be evaluated using patient/caregiver and clinician feedback regarding value, ease of use, and challenges with use, 2) effect of MAP on patient/caregiver knowledge and perception of medication use, 3) effect of MAP on adherence to inhaled and oral medications used in chronic management of CF. Preliminary data regarding outcomes on exacerbations, lung function, and health care system utilization (e.g., emergency department visits, hospitalization) will also be examined as part of this study.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Cystic Fibrosis Congenital, Hereditary, and Neonatal Diseases and Abnormalities Cystic Fibrosis in Children Digestive System Diseases Genetic Diseases, Inborn Infant, Newborn, Diseases Lung Diseases Pancreatic Diseases Respiratory Tract Diseases

Age range

12 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Children's of Alabama, Birmingham, Alabama, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • CLINICIAN PARTICIPANTS:
  • A CF care team member from any discipline, designated by the site principal investigator (PI) and CF team
  • Willing to use MAP as part of CF care
  • PATIENT PARTICIPANTS:
  • Male or female patients ages ≥ 12 years of age at Study Visit 1
  • Documentation of a CF diagnosis (physician diagnosed)
  • Ability to understand verbal and written English
  • Access to mobile device such as a tablet or smartphone (iPhone/iPad/iTouch or Android device)
  • Willingness to use the MAP application
  • Currently taking at least one of the following chronic medications and willing to use AdhereTech pill bottles for oral medications and/or eTrack nebulizer for nebulized medications listed below: nebulized agents, dornase alfa, hypertonic saline, inhaled tobramycin, inhaled aztreonam, inhaled colistimethate, oral agents, azithromycin
  • CAREGIVER PARTICIPANTS (for Patient Participants age < 18 years)
  • Child is consented to participate in the study.
  • Ability to understand verbal and written English

Exclusion criteria

  • CLINICIAN PARTICIPANTS:

Previous use of MAP (with patient(s) or self) in the last 12 months - when used with patients, defined as use in 5 or more patients

  • PATIENT PARTICIPANTS:
  • Previous use of MAP in the last 12 months - defined as use for 4 weeks or longer in own care
  • Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data including, but not limited to, diagnosis of intellectual or developmental disability (e.g., autism); and/or history of lung transplant
  • Planned or scheduled hospitalization during study period of up to 36 weeks
  • CAREGIVER PARTICIPANTS:

(for Patient Participants age < 18 years)

  • Previous use of MAP in the last 12 months - defined as use for 4 weeks or longer in child's or own care

Treatment and study plan

MedActionPlan®

Behavioral

web-based, mobile medication management application [MedActionPlan® (MAP)]

Other names: MAP

Primary outcomes

  1. mean score of Intervention Feasibility and Acceptability questionnaire (iFAQ) for patients assessed by likert scale

    Time frame: week 24

    This measure was developed for this specific study to evaluate feasibility and acceptability of patient use through aspects of usability and quality (engagement, usefulness, functionality/ease of use, aesthetics, information, and satisfaction) of the web portal and application. Assessed by 5 point Likert Scale: Strongly disagree, Disagree, Neither Agree or Disagree, Agree, Strongly Agree

  2. mean score of Intervention Feasibility and Acceptability questionnaire (iFAQ) for clinicians assessed by likert scale

    Time frame: up to 30 months

    This measure was developed for this specific study to evaluate feasibility and acceptability of clinician use through aspects of usability and quality (engagement, usefulness, functionality/ease of use, aesthetics, information, and satisfaction) of the web portal and application. Assessed by 5 point Likert Scale: Strongly disagree, Disagree, Neither Agree or Disagree, Agree, Strongly Agree

Secondary outcomes

  1. change in Knowledge of Disease Management-CF questionnaire (KDM-CF) scores

    Time frame: Day 1 to approximately week 24

    This validated measure was developed for studies of adherence and disease management. It assesses the practical knowledge of patients with CF. The measure evaluates knowledge of disease management in four areas (general health, lung health, nutrition, treatments).Data regarding changes in knowledge (using KDM-CF), from baseline to end of study visit, will be analyzed using Wilcoxon Signed Rank test. Data regarding changes in knowledge (using KDM-CF and CF-MQ) between groups (Intervention vs. Control) will be analyzed using Wilcoxon Rank Sum test.

  2. change in CF Medication Belief Questionnaire (CF-MBQ) scores

    Time frame: Day 1 to approximately week 24

    Developed and validated to measure impact of interventions on specific social cognitive beliefs. Data regarding perception of medications (using CF-MBQ), from baseline to end of study, will be analyzed using Wilcoxon Signed Rank test. Data regarding perception of medications (using CF-MBQ), between groups (Intervention vs. Control), will be analyzed using Wilcoxon Rank Sum test. The CF-MBQ has 60 questions. There are five domains for this measure: motivation, self-efficacy, perceived importance of medication, and decisional balance to take or miss medications. Questions related to self-efficacy, motivation and importance items use a scale from 1 to 10. Questions related to decisional balance use a scale based on a 1 to 5 scale. Scores for each subscale's items will be summed and divided by the number of items to produce an average score ranging from 1 to 10 (self-efficacy, motivation and importance) OR 1 to 5 (decisional balance).

  3. Mean change in adherence

    Time frame: Day 1 to approximately week 24

    Assess the preliminary effect of MAP on medication adherence from data collected from AdhereTech pill bottles and eTrack nebulizers that will be scored as a 'per drug analysis' of adherence with a ratio of competed to total prescribed doses in the study period. A composite score will be determined based on prescribed medications and medication/doses taken.

  4. change in CF Medication Questionnaire (CF-MQ) scores

    Time frame: Day 1 to approximately week 24

    Developed to assess Patient Participant knowledge about prescribed CF medications including purpose, dose, and administration. Question items will evaluate knowledge of medication purpose, administration, dose, and dosing frequency. Correct response for dose and dosing frequency will be based on each patient's prescribed regimen. Questions regarding medication purposes and appropriate administration each have 1 correct answer. Total score will be defined as proportion of correct items to total items asked. Each Patient Participant will only be asked about items that are associated with that Patient Participant's prescribed treatment plan. Total score for a Participant will not be calculated if greater than 20% of the items are missing responses.

Sponsors and collaborators

Lead sponsor

Boston Children's Hospital

Other

Collaborators

  • Cystic Fibrosis Foundation
  • Johns Hopkins University
  • University of Arizona

Registry information

Acronym: MAP

Important dates

Study start
2018
Primary completion
2020
Study completion
2021
First posted
Aug 20, 2018
Registry last updated
Aug 3, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.